Article Sidebar

PDF
Date Published: 14/11/2023
Abstract Views: 87
Views PDF: 33
DOI: https://doi.org/10.56283/1859-0381/630
Issue
Vol. 19 No. 6 (2023)
Section
ORIGINAL RESEARCH
How to Cite
1.
TRAN TN, PHAM NK, LE MH. EFFECTIVENESS OF KENU TD CAPSULES IN SUPPORTING THE TREATMENT OF TYPE 2 DIABETES. Tạp chí Dinh dưỡng và Thực phẩm. 2023;19(6):20-26. doi:10.56283/1859-0381/630

EFFECTIVENESS OF KENU TD CAPSULES IN SUPPORTING THE TREATMENT OF TYPE 2 DIABETES

Thi Nuong TRAN1,, Ngoc Khai PHAM1, Minh Hieu LE1
1 Thai Binh University of Medicine and Pharmacy

Main Article Content

Abstract

Aims: To evaluate the effectiveness treatment of KENU TD capsules in patients with type 2 diabetes.


Methods: A randomized open-label clinical trial was conducted in 472 outpatients receiving drugs for type 2 diabetes. The intervention group received KENU TD capsules for 3 months (n=237). The effectiveness of KENU TD capsules on HbA1c reduction and blood glucose control was evaluated using a generalized linear model with adjustment for factors including age, gender, residence, physical activity, smoking, alcohol consumption, body mass index, systolic blood pressure, HbA1c, fasting blood glucose, insulin injection, complications, total cholesterol, LDL-Cholesterol, triglyceride at baseline and BMI change after intervention.


Results: The average HbA1c decreased by 0.59% in the intervention group and decreased by 0.18% in the control group (p = 0.001). Using the product could achieve better blood glucose control (HbA1c <7 mmol/L) than not using the product with aRR (95%CI)= 0.65 (0.49-0.85).


Conclusion: Using KENU TD capsules 3 months could effectively reduce HbA1c in patients with type 2 diabetes and increase the likelihood of achieving goal for blood glucose control.

Article Details

Keywords

KENU TD, đái tháo đường týp 2, hỗ trợ điều trị

References

1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.
2. Gong J, Fang K, Dong H, et al. Effect of fenugreek onhyperglycaemia and hyperlipidemia in diabetes and prediabetes: Ameta-analysis. Journal of Ethnopharmacology. 2016;194:260–268.
3. Chatterji S and Fogel D. Study of the effect of the herbal composition SR2004 on hemoglobin A1c, fasting blood glucose, and lipids in patients with type 2 diabetes mellitus. Integr Med Res. 2018;7(3):248–256.
4. Nguyen KT, Diep BTT, Nguyen VDK, et al. A cross-sectional study to evaluate diabetes management, control and complications in 1631 patients with type 2 diabetes mellitus in Vietnam (DiabCare Asia). Int J Diabetes Dev Ctries. 2020;40(1):70–7
5. Genuth S, Eastman R, Kahn R, et al. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2003;26:28-32.
6. Rawshani A, Rawshani A, Franzén S, et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018;379(7):633–644.
7. Guo C, Li R, Zheng N, et al. Anti-diabetic effect of ramulus mori polysaccharides, isolated from Morus alba L., on STZ-diabetic mice through blocking inflammatory response and attenuating oxidative stress. International Immunopharmacology. 2013;16(1):93–99.
8. Kim ES, Park SJ, Lee EJ, et al. (1999). Purification and characterization of Moran 20K from Morus alba. Arch Pharm Res, 22(1): 9–12.